Raymond James Financial
TBPH icon

Raymond James Financial’s Theravance Biopharma TBPH Stock Holding History

Raymond James Financial’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-692
Closed -$7.63K – 6591
2025
Q2 		$7.63K Buy
+692
New +$6.73K ﹤0.01% 6035

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Raymond James Financial's TBPH Position: Q3 2025 in Review

Raymond James Financial sold out of Theravance Biopharma (TBPH) in Q3 2025, closing a stake of 692 shares — an estimated $7.63K sold.

Raymond James Financial first reported a position in TBPH in Q2 2025 and held it in 1 quarter. The position peaked at $7.63K in Q2 2025. 162 funds tracked by Wall St. Rank hold TBPH as of Q3 2025.

  • Raymond James Financial reported no remaining Theravance Biopharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 692 Theravance Biopharma shares in Q3 2025, an estimated $7.63K.
  • Raymond James Financial first reported a position in Theravance Biopharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Theravance Biopharma position peaked at $7.63K in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.